PolarityTE Leadership to Participate in the Symposium on Advanced Wound Care

SALT LAKE CITY, April 26, 2018 (GLOBE NEWSWIRE) -- PolarityTE, Inc. (Nasdaq:COOL) today announced attendance and participation in the Symposium on Advanced Wound Care Spring (SAWC Spring) Wound Healing Society (WHS) meeting being held in Charlotte, North Carolina through April 29, 2018.

The Symposium on Advanced Wound Care is the world’s largest multidisciplinary conference dedicated to the advancement of wound care and healing. The forum connects the entire wound care team — physicians, nurses, physical therapists, researchers, scientists, podiatrists and dietitians — with the foremost experts in wound care to improve patient outcomes through education.

During the Thursday morning sessions at the conference, PolarityTE Chief Clinical Officer Stephen Milner, MD, DDS, DSc, FACS will speak about the role of debridement in the clinical care of wounds. As a leader in the field, Dr. Milner was invited to present relying on his years of experience as the Director of the Johns Hopkins Regional Burn Center and Professor of Plastic and Reconstructive Surgery at Johns Hopkins University School of Medicine.

Further, members of the PolarityTE Clinical Operations team will be hosting meetings with providers throughout the conference to educate them about SkinTE™ – a human cellular and tissue-based product derived from a patient’s own skin to regenerate full-thickness, functionally-polarized skin with all its layers (epidermis, dermis and hypodermis) and appendages, including hair follicles and glands. SkinTE, for the repair, reconstruction and replacement of full-thickness skin, has been used in the treatment of chronic wounds during the limited-market release, and it has the potential to change the wound care field by providing a novel, full-thickness treatment option.

“At PolarityTE we believe that patients need better options and more effective healing after functional loss of their skin, and we look forward to taking advantage of another opportunity to connect with providers about SkinTE and PolarityTE’s completely new approach to regenerative medicine,” said Dr. Denver Lough, CEO of PolarityTE.  

About PolarityTE™
PolarityTE is a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. The PolarityTE platform technology begins with a small piece of the patient’s own, or autologous, healthy tissue, rather than artificially manipulated individual cells. From this small piece of healthy autologous tissue, the company creates an easily deployable, dynamic and self-propagating product designed to enhance and stimulate the patient’s own cells to regenerate the target tissues. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, PolarityTE manufactures with the patient’s own tissue and uses the patient’s own body to support the regenerative process to create the same tissue from which it was derived. PolarityTE’s innovative method is intended to promote and accelerate growth of the patient’s tissues to undergo a form of effective regenerative healing.

About SkinTE™
SkinTE is intended to be used by physicians or other appropriate healthcare providers for homologous uses of skin tissues/integument. Patients who have suffered from an event, disease, process or acquired deficit that results in the functional loss or void of skin/integument systems can receive SkinTE as an adjunct and/or in place of split-thickness skin grafting, full-thickness grafting, temporizing skin coverage and/or skin substitute products.

SkinTE is for autologous use only. Aseptic technique during harvest and deployment of SkinTE is mandatory. SkinTE use is contraindicated in patients who have suffered autoimmune responses to the auto-transplantation of their own tissues.

SkinTE is regulated by the FDA as an HCT/P solely under Section 361 of the Public Health Service Act and 21 CFR 1271. The FDA has specific regulations governing HCT/Ps. HCT/Ps that meet the criteria for regulation solely under Section 361 of the Public Health Service Act and 21 CFR 1271 (361 HCT/Ps) are not subject to pre-market clearance or approval requirements, but are subject to post-market regulatory requirements.

Forward Looking Statements
Certain statements contained in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements contained in this release relate to, among other things, the Company’s ongoing compliance with the requirements of The NASDAQ Stock Market and the Company’s ability to maintain the closing bid price requirements of The NASDAQ Stock Market on a post reverse split basis. They are generally identified by words such as “believes,” “may,” “expects,” “anticipates,” “intend,” “plan,” “will,” “would,” “should” and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company’s beliefs and assumptions as of the date of this release. The Company’s actual results could differ materially due to risk factors and other items described in more detail in the “Risk Factors” section of the Company’s Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law. Our actual results could differ materially due to risk factors and other items described in more detail in the “Risk Factors” section of the Company’s Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov).

CONTACT

Investors:
John Stetson
InvestorRelations@PolarityTE.com
(385) 237-2365

Hans Vitzthum
LifeSci Advisors, LLC
Hans@LifeSciAdvisors.com
(617) 535-7743

Media:
David Schull
Russo Partners LLC
David.Schull@RussoPartnersLLC.com 
(858) 717-2310

Jenna Mathis
jennamathis@polarityte.com
(610) 751-3985